# Study to Determine Optimum Intravenous Starting Dose of MIRCERA for Treatment of Pediatric Participants With Anemia and Chronic Kidney Disease on Hemodialysis

> **NCT00717366** · PHASE2 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 64 (actual)

## Conditions studied

- Renal Anemia

## Interventions

- **DRUG:** Methoxy Polyethylene Glycol-Epoetin Beta

## Key facts

- **NCT ID:** NCT00717366
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-07
- **Primary completion:** 2016-03
- **Final completion:** 2016-03
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2017-09-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00717366

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00717366, "Study to Determine Optimum Intravenous Starting Dose of MIRCERA for Treatment of Pediatric Participants With Anemia and Chronic Kidney Disease on Hemodialysis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00717366. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*